Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 18, Issue 1, Pages 28-37
Publisher
Wiley
Online
2015-12-04
DOI
10.1002/ejhf.444
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
- (2015) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy
- (2015) Luis M. Ruilope et al. AMERICAN JOURNAL OF NEPHROLOGY
- Updated National and International Hypertension Guidelines: A Review of Current Recommendations
- (2014) Sverre Kjeldsen et al. DRUGS
- Serum Aldosterone and Death, End-Stage Renal Disease, and Cardiovascular Events in Blacks and Whites
- (2014) Rajat Deo et al. HYPERTENSION
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Comparison of Agents That Affect Aldosterone Action
- (2014) Juan Tamargo et al. SEMINARS IN NEPHROLOGY
- Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction
- (2013) Srinivas R. Bapoje et al. Circulation-Heart Failure
- Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy
- (2013) Patrick Rossignol et al. Circulation-Heart Failure
- The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?
- (2013) Johann Bauersachs EUROPEAN HEART JOURNAL
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey
- (2013) Vincent M. van Deursen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function
- (2013) Romain Eschalier et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis
- (2012) Li-jun Hu et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
- (2012) et al. EUROPEAN JOURNAL OF HEART FAILURE
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats
- (2012) Tetsuro Nariai et al. PHARMACOLOGY
- Mechanisms of ligand specificity of the mineralocorticoid receptor
- (2011) Peter J Fuller et al. JOURNAL OF ENDOCRINOLOGY
- A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
- (2011) Hari K Parthasarathy et al. JOURNAL OF HYPERTENSION
- SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity
- (2011) Tetsuro Nariai et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
- (2011) Rena J Eudy et al. Journal of Translational Medicine
- Aldosterone, mineralocorticoid receptor, and heart failure
- (2011) Smail Messaoudi et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats
- (2010) Nicole Schupp et al. FASEB JOURNAL
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of (3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy
- (2010) Marvin J. Meyers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines
- (2010) Graciela B. Arhancet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aldosterone antagonists are underused by clinicians
- (2010) Jane-Lise Samuel et al. Nature Reviews Cardiology
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
- (2009) Lisa M. Einhorn et al. ARCHIVES OF INTERNAL MEDICINE
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
- (2009) Alessandro Boccanelli et al. EUROPEAN JOURNAL OF HEART FAILURE
- Glucocorticoids Activate Cardiac Mineralocorticoid Receptors During Experimental Myocardial Infarction
- (2009) Anastasia S. Mihailidou et al. HYPERTENSION
- Reconsidering the Roles of the Mineralocorticoid Receptor
- (2009) John W. Funder HYPERTENSION
- The mineralocorticoid receptor and its coregulators
- (2009) Jun Yang et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Aldosterone causes DNA damage in vitro and in kidneys of DOCA/salt rats, mediated by the mineralocorticoid receptor
- (2009) Nicole Schupp et al. TOXICOLOGY LETTERS
- Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
- (2008) Bertram Pitt et al. CIRCULATION
- A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity
- (2008) Jessica D. Dietz et al. HYPERTENSION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started